Loxo Oncology Inc. (NASDAQ:LOXO) shares saw strong trading volume on Wednesday . 537,427 shares changed hands during trading, an increase of 434% from the previous session’s volume of 100,566 shares.The stock last traded at $27.00 and had previously closed at $27.43.

A number of research analysts recently weighed in on the company. Oppenheimer Holdings Inc. reaffirmed an “outperform” rating and set a $30.00 price objective on shares of Loxo Oncology in a report on Tuesday, April 19th. Zacks Investment Research raised Loxo Oncology from a “sell” rating to a “hold” rating in a report on Thursday, May 5th. Cowen and Company reaffirmed a “buy” rating on shares of Loxo Oncology in a report on Wednesday, July 13th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and set a $36.00 price objective on shares of Loxo Oncology in a report on Monday, April 18th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $29.60.

The stock’s market cap is $559.58 million. The company has a 50 day moving average price of $24.95 and a 200-day moving average price of $23.47.

Loxo Oncology (NASDAQ:LOXO) last released its quarterly earnings data on Wednesday, August 3rd. The biopharmaceutical company reported ($0.77) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.63) by $0.14. Analysts predict that Loxo Oncology Inc. will post ($2.83) EPS for the current year.

In other news, major shareholder Aisling Capital Iii Lp acquired 232,558 shares of Loxo Oncology stock in a transaction that occurred on Tuesday, May 17th. The stock was purchased at an average price of $21.50 per share, with a total value of $4,999,997.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

An institutional investor recently bought a new position in Loxo Oncology stock. GSA Capital Partners LLP acquired a new position in shares of Loxo Oncology Inc. (NASDAQ:LOXO) during the fourth quarter, according to its most recent disclosure with the SEC. The firm acquired 37,100 shares of the biopharmaceutical company’s stock, valued at approximately $1,055,000. GSA Capital Partners LLP owned 0.22% of Loxo Oncology at the end of the most recent reporting period.

Loxo Oncology, Inc is a United States-based biopharmaceutical company. The Company is engaged in developing selective medicines for patients with genetically defined cancers. Its pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.